This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 May;123(5):1772; author reply 1772-3.

doi: 10.1378/chest.123.5.1772.

Sitaxsentan in pulmonary arterial hypertension

Sotiria C Apostolopoulou, Spyridon Rammos

PMID: 12740304
DOI: 10.1378/chest.123.5.1772

Comment

Sitaxsentan in pulmonary arterial hypertension

Sotiria C Apostolopoulou et al. Chest. 2003 May.

. 2003 May;123(5):1772; author reply 1772-3.

doi: 10.1378/chest.123.5.1772.

Authors

Sotiria C Apostolopoulou, Spyridon Rammos

PMID: 12740304
DOI: 10.1378/chest.123.5.1772

No abstract available

PubMed Disclaimer

Comment on

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.
Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Barst RJ, et al. Chest. 2002 Jun;121(6):1860-8. doi: 10.1378/chest.121.6.1860. Chest. 2002. PMID: 12065350 Clinical Trial.

Similar articles

Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.
Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Barst RJ, et al. Chest. 2002 Jun;121(6):1860-8. doi: 10.1378/chest.121.6.1860. Chest. 2002. PMID: 12065350 Clinical Trial.
Sitaxsentan sodium for pulmonary hypertension.
MacIntyre IM, Dhaun N, Goddard J, Webb DJ. MacIntyre IM, et al. Drugs Today (Barc). 2008 Aug;44(8):585-600. doi: 10.1358/dot.2008.44.8.1239808. Drugs Today (Barc). 2008. PMID: 18846270 Review.
Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.
Barst RJ. Barst RJ. Expert Opin Pharmacother. 2007 Jan;8(1):95-109. doi: 10.1517/14656566.8.1.95. Expert Opin Pharmacother. 2007. PMID: 17163810 Review.
Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.
Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Langleben D, et al. Chest. 2004 Oct;126(4):1377-81. doi: 10.1378/chest.126.4.1377. Chest. 2004. PMID: 15486408
A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
Waxman AB. Waxman AB. Vasc Health Risk Manag. 2007;3(1):151-7. Vasc Health Risk Manag. 2007. PMID: 17583185 Free PMC article. Review.

See all similar articles

Cited by

Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension.
Tulloh R. Tulloh R. Paediatr Drugs. 2009;11(2):115-28. doi: 10.2165/00148581-200911020-00003. Paediatr Drugs. 2009. PMID: 19301933 Review.
Treatment of pediatric pulmonary hypertension.
Hawkins A, Tulloh R. Hawkins A, et al. Vasc Health Risk Manag. 2009;5(2):509-24. doi: 10.2147/vhrm.s4171. Epub 2009 Jun 7. Vasc Health Risk Manag. 2009. PMID: 19554091 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information